Flamel Technologies SA (FLML) Expected to Earn FY2016 Earnings of ($0.12) Per Share
Flamel Technologies SA (NASDAQ:FLML) – Investment analysts at Leerink Swann boosted their FY2016 earnings estimates for Flamel Technologies SA in a report issued on Tuesday. Leerink Swann analyst J. Gerberry now expects that the brokerage will post earnings of ($0.12) per share for the year, up from their previous forecast of ($0.19). Leerink Swann currently has a “Outperform” rating and a $16.00 price target on the stock. Leerink Swann also issued estimates for Flamel Technologies SA’s Q4 2016 earnings at ($0.06) EPS, FY2017 earnings at $0.29 EPS, FY2018 earnings at $0.66 EPS, FY2019 earnings at $0.44 EPS and FY2020 earnings at $0.37 EPS.
FLML has been the topic of a number of other research reports. Zacks Investment Research upgraded Flamel Technologies SA from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a report on Tuesday, October 18th. JMP Securities reiterated an “outperform” rating and set a $16.00 price target on shares of Flamel Technologies SA in a report on Wednesday, September 28th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Flamel Technologies SA presently has an average rating of “Buy” and an average target price of $17.70.
Shares of Flamel Technologies SA (NASDAQ:FLML) opened at 10.81 on Thursday. The firm’s 50-day moving average price is $0.00 and its 200 day moving average price is $0.00. Flamel Technologies SA has a 12-month low of $7.56 and a 12-month high of $15.54.
Flamel Technologies SA (NASDAQ:FLML) last announced its earnings results on Monday, November 7th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.13. The business had revenue of $32.10 million for the quarter, compared to the consensus estimate of $30.70 million. Flamel Technologies SA had a return on equity of 17.33% and a net margin of 18.25%. The company’s revenue was down 32.1% on a year-over-year basis. During the same period last year, the business posted $0.28 EPS.
Hedge funds have recently added to or reduced their stakes in the company. KCG Holdings Inc. bought a new stake in Flamel Technologies SA during the third quarter valued at about $240,000. Morgan Stanley increased its stake in Flamel Technologies SA by 18.1% in the third quarter. Morgan Stanley now owns 1,103,494 shares of the company’s stock valued at $13,683,000 after buying an additional 168,772 shares during the period. Bailard Inc. increased its stake in Flamel Technologies SA by 17.2% in the third quarter. Bailard Inc. now owns 120,700 shares of the company’s stock valued at $1,497,000 after buying an additional 17,700 shares during the period. Ameriprise Financial Inc. increased its stake in Flamel Technologies SA by 6.8% in the third quarter. Ameriprise Financial Inc. now owns 176,357 shares of the company’s stock valued at $2,174,000 after buying an additional 11,166 shares during the period. Finally, Baldwin Brothers Inc. MA increased its stake in Flamel Technologies SA by 116.3% in the third quarter. Baldwin Brothers Inc. MA now owns 9,300 shares of the company’s stock valued at $115,000 after buying an additional 5,000 shares during the period. Institutional investors own 70.42% of the company’s stock.
In other news, CEO Michael S. Anderson bought 5,000 shares of the stock in a transaction on Monday, August 22nd. The shares were purchased at an average price of $14.30 per share, for a total transaction of $71,500.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Francis Fildes sold 15,000 shares of the business’s stock in a transaction dated Thursday, September 22nd. The shares were sold at an average price of $13.45, for a total value of $201,750.00. Following the completion of the transaction, the director now owns 15,000 shares in the company, valued at approximately $201,750. The disclosure for this sale can be found here. 4.45% of the stock is owned by company insiders.
Flamel Technologies SA Company Profile
Flamel Technologies SA is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its polymer based technology. The Company has a balanced business model consisting of an Unapproved Marketed Drugs (UMDs) business with over two approved products in the United States, Bloxiverz (neostigmine methylsulfate injection) and Vazculep (phenylephrine hydrochloride injection) that are marketed; a branded pediatric business, and a branded business, focusing on the development of products utilizing Flamel’s drug delivery platforms.
Receive News & Stock Ratings for Flamel Technologies SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flamel Technologies SA and related stocks with our FREE daily email newsletter.